# Sarah Cannon Research Institute

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/sarah-cannon-research-institute/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 66.3 |
| Citations | 98,097 |
| City | London |
| Country | GB |
| Description | Sarah Cannon Research Institute is a research organisation in London, GB. OpenAlex records 1,566 works and 98,097 citations for it. 281 researchers list it as their most recent affiliation. |
| Homepage | http://sarahcannonresearch.co.uk/ |
| OpenAlex ID | https://openalex.org/I172427033 |
| Researchers | 281 |
| ROR ID | https://ror.org/03cp5cj42 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q7422164 |
| Works | 1,566 |

## University papers

Showing 12 of 25.

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation](https://scholariq.org/papers/sotorasib-for-lung-cancers-with-i-kras-i-p-g12c-mutation/)
- [KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation](https://scholariq.org/papers/adagrasib-in-non-small-cell-lung-cancer-harboring-a-i-kras-sup-g12c-sup-i/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial](https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.